Code Biotherapeutics
PrivateLast Round
Series A
Jun 7, 2022
Total Funding Raised
$85M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Code Biotherapeutics operates in Healthcare & Life Sciences and is based in Hatfield, Pennsylvania. Its latest recorded funding round was a Series A round in June 2022.
Code Biotherapeutics is a biotechnology company that develops non-viral gene therapies for serious and life-threatening genetic disorders using its proprietary 3DNA delivery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Code Biotherapeutics Comparables
Compare Code Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BreezeBio | 87% | |
| Resilience | 81% | |
| SYTE.bio | 81% |
For institutional investors. Book with your work email.
Code Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 7, 2022 | ||||
| Seed | Apr 20, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Code Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCB Ventures | Series A |
| CureDuchenne Ventures | Seed, Series A |
| New Enterprise Associates | Series A, Seed |
| Hatteras Venture Partners | Series A |
| 4BIO Capital | Series A, Seed |
| UCB Ventures | Series A |
| Northpond Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 45% MoM, reaching 1.4K.
- Jun 7, 2022
$75M round led by Northpond Ventures.
For institutional investors. Book with your work email.
Code Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Code Biotherapeutics's valuation, stock price, and market status.
Is Code Biotherapeutics a public or private company?
Code Biotherapeutics is a private company.
What is the current stock price of Code Biotherapeutics?
Code Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Code Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Code Biotherapeutics worth (valuation)?
Valuation information for Code Biotherapeutics is not publicly available.
Can I buy Code Biotherapeutics stock?
Code Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Code Biotherapeutics's last funding round?
Code Biotherapeutics's most recent funding round was Series A on June 7, 2022.
Who are the main investors in Code Biotherapeutics?
Key investors in Code Biotherapeutics include 4BIO Capital, Northpond Ventures, Northpond Ventures, UPMC Enterprises.
Will Code Biotherapeutics IPO soon?
No public IPO plans have been announced for Code Biotherapeutics.
How can I track Code Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Code Biotherapeutics's shares on secondary markets.